期刊文献+

Breast Conserving Surgery: Has the Standard of Care Enhanced Outcomes for Patients?

Breast Conserving Surgery: Has the Standard of Care Enhanced Outcomes for Patients?
在线阅读 下载PDF
导出
摘要 Breast Conserving Surgery (BCS) is a rapidly emerging field increasingly adopted to facilitate breast conservation and preserve breast aesthetics. Since the publicatio</span><span style="font-family:Verdana;">n of the Randomized Controlled Trials (RCTs) of Breast Conserving Surgery versus mastectomy in early breast cancer, the adoption of BCS for breast cancer patients’ surgical management has been comprehensive. A computerized bibliographic search was performed on PubMed/MEDLINE,</span><span style="font-family:Verdana;"> Embase, Google Scholar and Cochrane library databases. This article aims to perform a thorough review of new data regarding invasive cancer and margins while evaluating patient outcomes related to BCS after neoadjuvant chemotherapy focusing on margins, imaging evaluation, the extent of resection, and local regional recurrence outcomes. The growth pattern and biopsy of Ductal Carcinoma </span><i><span style="font-family:Verdana;">In Situ</span></i><span style="font-family:Verdana;"> (DCIS) differ from invasive cancer, impacting margins. It is essential to understand how the Society of Surgical Oncology (SSO) DCIS margin guideline has influenced practice. Early breast cancer surgical management should be unique to each patient, driven by evidence-based medicine, and focused on specific clinical, histological, and molecular characteristics of the tumor. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">The current management for early breast cancer should be tailored and evidence-based to each patient based on the clinical, histological and molecular characteristics of the tumor. Presumably, the standard of care in BCS has enhanced the outcomes for this patient population. This review made by peers will help surgeons to stay up to date with the current literature and help them manage breast cancer while improving multiple clinical parameters such as Disease-Free Survival (DFS), Recurrence-Free Survival (RFS) and most importantly Overall Survival (OS)</span></span></span><span style="font-family:Verdana;">. Breast Conserving Surgery (BCS) is a rapidly emerging field increasingly adopted to facilitate breast conservation and preserve breast aesthetics. Since the publicatio</span><span style="font-family:Verdana;">n of the Randomized Controlled Trials (RCTs) of Breast Conserving Surgery versus mastectomy in early breast cancer, the adoption of BCS for breast cancer patients’ surgical management has been comprehensive. A computerized bibliographic search was performed on PubMed/MEDLINE,</span><span style="font-family:Verdana;"> Embase, Google Scholar and Cochrane library databases. This article aims to perform a thorough review of new data regarding invasive cancer and margins while evaluating patient outcomes related to BCS after neoadjuvant chemotherapy focusing on margins, imaging evaluation, the extent of resection, and local regional recurrence outcomes. The growth pattern and biopsy of Ductal Carcinoma </span><i><span style="font-family:Verdana;">In Situ</span></i><span style="font-family:Verdana;"> (DCIS) differ from invasive cancer, impacting margins. It is essential to understand how the Society of Surgical Oncology (SSO) DCIS margin guideline has influenced practice. Early breast cancer surgical management should be unique to each patient, driven by evidence-based medicine, and focused on specific clinical, histological, and molecular characteristics of the tumor. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">The current management for early breast cancer should be tailored and evidence-based to each patient based on the clinical, histological and molecular characteristics of the tumor. Presumably, the standard of care in BCS has enhanced the outcomes for this patient population. This review made by peers will help surgeons to stay up to date with the current literature and help them manage breast cancer while improving multiple clinical parameters such as Disease-Free Survival (DFS), Recurrence-Free Survival (RFS) and most importantly Overall Survival (OS)</span></span></span><span style="font-family:Verdana;">.
作者 Rodrigo Arrangoiz Jeronimo Garcialopez De Llano Maria Fernanda Mijares Gonzalo Fernandez-Christlieb Vanitha Vasudevan Amit Sastry Adrian Legaspi Rodrigo Arrangoiz;Jeronimo Garcialopez De Llano;Maria Fernanda Mijares;Gonzalo Fernandez-Christlieb;Vanitha Vasudevan;Amit Sastry;Adrian Legaspi(Center for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, USA;Center for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, USA)
出处 《Advances in Breast Cancer Research》 2021年第1期1-23,共23页 乳腺癌(英文)
关键词 Breast Conserving Surgery (BCS) Disease-Free Survival (DFS) Recur-rence-Free Survival (RFS) Distant-Disease-Free Survival (DDFS) Overall Sur-vival (OS) Ductal Carcinoma in Situ (DCIS) Neoadjuvant Chemotherapy (NAC) Breast Conserving Surgery (BCS) Disease-Free Survival (DFS) Recur-rence-Free Survival (RFS) Distant-Disease-Free Survival (DDFS) Overall Sur-vival (OS) Ductal Carcinoma in Situ (DCIS) Neoadjuvant Chemotherapy (NAC)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部